Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/imcb.12404

http://scihub22266oqcxt.onion/10.1111/imcb.12404
suck pdf from google scholar
32924178!ä!32924178

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32924178      Immunol+Cell+Biol 2021 ; 99 (2): 168-176
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • The future is now? Clinical and translational aspects of "Omics" technologies #MMPMID32924178
  • D'Adamo GL; Widdop JT; Giles EM
  • Immunol Cell Biol 2021[Feb]; 99 (2): 168-176 PMID32924178show ga
  • Big data has become a central part of medical research, as well as modern life generally. "Omics" technologies include genomics, proteomics, microbiomics and increasingly other omics. These have been driven by rapid advances in laboratory techniques and equipment. Crucially, improved information handling capabilities have allowed concepts such as artificial intelligence and machine learning to enter the research world. The COVID-19 pandemic has shown how quickly information can be generated and analyzed using such approaches, but also showed its limitations. This review will look at how "omics" has begun to be translated into clinical practice. While there appears almost limitless potential in using big data for "precision" or "personalized" medicine, the reality is that this remains largely aspirational. Oncology is the only field of medicine that is widely adopting such technologies, and even in this field uptake is irregular. There are practical and ethical reasons for this lack of translation of increasingly affordable techniques into the clinic. Undoubtedly, there will be increasing use of large data sets from traditional (e.g. tumor samples, patient genomics) and nontraditional (e.g. smartphone) sources. It is perhaps the greatest challenge of the health-care sector over the coming decade to integrate these resources in an effective, practical and ethical way.
  • |Artificial Intelligence/trends[MESH]
  • |COVID-19/epidemiology[MESH]
  • |Genomics/methods/*trends[MESH]
  • |Humans[MESH]
  • |Medical Oncology/methods/trends[MESH]
  • |Metabolomics/methods/*trends[MESH]
  • |Pandemics[MESH]
  • |Precision Medicine/methods/*trends[MESH]
  • |Proteomics/methods/trends[MESH]
  • |Time Factors[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box